Pharmasyntez has been granted a registration certificate by the Ministry of Health of the Russian Federation for Paliperidone, an antipsychotic medication containing the same active ingredient. This is an analogue of Invega from Johnson & Johnson, used in Russia for the treatment of schizophrenia since 2007.
Paliperidone is available in tablet form in three dosages: 3, 6 and 9 mg. The drug relieves hallucinations and delusions, fights anxiety and depression, and normalizes sleep. Prescribed to patients aged 12 to 17 years.
May this year Teva Pharmaceuticals and MedinCell have received approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone) extended-release injectable suspension to treat adult patients with schizophrenia, a chronic, progressive, and severely debilitating mental health disorder.
